Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue$2.64M$2.64M−28.3% vs Q1 2016 Net Income-$2.57M-$2.57MN/M vs Q1 2016 EPS Diluted-$0.61-$0.61N/M vs Q1 2016 Gross Profit$981,000−47.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$2,377,000N/M Free Cash Flowderived-$2,391,000N/M Margins · derivedGross margin37.2%−13.7 pt vs Q1 2016
Operating margin-133.0%−70.2 pt vs Q1 2016
Net margin-97.3%−33.8 pt vs Q1 2016
ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end